ERBB2 and neoplasm: A later breast CoC study identified PI3Kα and ErbB2 mutations as critical promoters of tumor invasion and enhanced tumor permeability, with PI3Kα mutation causing more rapid invasion.[82] Accordingly, new therapeutics can be designed to target these mutations.[268]